Blog
RSS FeedPosted by Michael Wonder on 23 Apr 2019
PHARMAC reportedly has rejected funding for breast cancer drug
23 April 2019 - A breast cancer support group has been told that PHARMAC has rejected funding for the drug ...
Posted by Michael Wonder on 24 Apr 2019
AbbVie expands immunology portfolio in the U.S. with FDA approval of Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis
23 April 2019 - AbbVie today announced that the U.S. FDA approved Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of ...
Posted by Michael Wonder on 23 Apr 2019
ICER's growing impact on drug pricing and reimbursement
17 April 2019 - The Institute for Clinical and Economic Review is sometimes called America's `NICE,’ referring to the National ...
Posted by Michael Wonder on 23 Apr 2019
Top-down government efforts to corral drug prices will fail
23 April 2019 - Americans pay a lot for pharmaceuticals, and politicians of all stripes are offering prescription drug price-relief ...
Posted by Michael Wonder on 23 Apr 2019
Ending drug rebates will not reduce drug prices
22 April 2019 - There are many reasons why drug prices are so high, beginning with the fact that it ...
Posted by Michael Wonder on 23 Apr 2019
Canadians will wait longer for new medicines if Health Canada gets its way
23 April 2019 - The intention is to lower prices; the net result will likely be longer wait times before new ...
Posted by Michael Wonder on 23 Apr 2019
PHARMAC rejects own experts' view on breast cancer drug
23 April 2019 - PHARMAC has refused funding for Kadcyla, an important drug that has recently had a high media ...
Posted by Michael Wonder on 23 Apr 2019
Pharma lobby nears spending records with drug prices under fire
23 April 2019 - Drug makers, groups disclose first-quarter spending increases. ...
Posted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...
Posted by Michael Wonder on 23 Apr 2019
FDA permits marketing of first medical device for treatment of ADHD
19 April 2019 - The U.S. FDA today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder. ...
Posted by Michael Wonder on 23 Apr 2019
Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?
23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines. ...
Posted by Michael Wonder on 23 Apr 2019
Intensity Therapeutics receives fast track designation from U.S. FDA for development of INT230-6 as treatment for relapsed or metastatic triple negative breast cancer
17 April 2019 - Intensity Therapeutics today announced that the U.S. FDA has granted fast track designation to the Company’s ...
Posted by Michael Wonder on 23 Apr 2019
FDA approves Merck’s Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as first-line treatment for patients with advanced renal cell carcinoma
22 April 2019 - Approval based on results of KEYNOTE-426, where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 23 Apr 2019
US FDA approves Duaklir Pressair (aclidinium/formoterol) for patients with chronic obstructive pulmonary disease
17 April 2019 - Only twice-daily LAMA /LABA in the United States with COPD exacerbation data included in its prescribing information. ...
Posted by Michael Wonder on 23 Apr 2019
More than 1 million Americans have lost health insurance since 2016
19 April 2019 - More than 1 million Americans have lost health insurance coverage since 2016, according to a new ...